Antibody-enhancing technologies
Kyowa Kirin owns proprietary antibody-enhancing technologies, POTELLIGENT® and COMPLEGENT®.
POTELLIGENT®Technology
Antibody is composed of sugar chains and polypeptide chains.
We discovered that removal of a sugar residue called fucose from the sugar chains lead to enhancement of ADCC activity of the therapeutic antibody.
COMPLEGENT® technology
Using protein engineering technology, we created "isotype-chimeric" antibody with enhanced CDC activity.
AccretaMab® technology
AccretaMab® is the result of our proprietary antibody enhancing technologies, POTELLIGENT® and COMPLEGENT®.
AccretaMab® features the ultimate combination of enhanced ADCC and CDC effector function.
